Yahoo! Finance: Biotechnology Industry News: Oral Apremilast Achieves Statistical Significance for the Primary Endpoint of PASI-75 in the First Phase III Study (ESTEEM 1) in Patients with Psoriasis

Yahoo! Finance: Biotechnology Industry News The latest news on the Biotechnology industry from Yahoo! Finance

Oral Apremilast Achieves Statistical Significance for the Primary Endpoint of PASI-75 in the First Phase III Study (ESTEEM 1) in Patients with Psoriasis Mar 2nd 2013, 16:20 [Business Wire] - Celgene International Sàrl, a subsidiary of Celgene Corporation today presented the results from ESTEEM 1, the Company's first phase III study in psoriasis, at the A

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions